Volrustomig Clinical Trials

8 actively recruiting trials across 6 locations

▼ -2 trials since August 2026

Also known as: MEDI5752, Other Name: MEDI5752

Pipeline

Phase 1: 1Phase 2: 6Phase 3: 1

Top Sponsors

AstraZeneca7
University of Chicago1

Indications

Cancer8
Gastric Cancer2
Lung Cancer2
Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)1
Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)1

Los Angeles, California3 trials

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Research Site

Phase 2

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Research Site

Phase 2

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Research Site

Phase 2

Birmingham, Alabama1 trial

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

Research Site

Phase 3

Scottsdale, Arizona1 trial

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Research Site

Phase 2

Little Rock, Arkansas1 trial

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site

Phase 2

Duarte, California1 trial

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Research Site

Phase 1

Chicago, Illinois1 trial

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

The University of Chicago

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.